Clinical Trial Update: Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical study evaluating the effect of CimetrA in patients diagnosed with COVID-19 is listed, with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corona Virus Infection
• Sars-cov Infection

Drugs mentioned

• CimetrA

Snippet

Sponsor: MGC Pharmaceuticals d.o.o | Conditions: Corona Virus Infection, Covid19 | Phase 3 | Status: UNKNOWN